Cargando…

A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya

OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which...

Descripción completa

Detalles Bibliográficos
Autores principales: Bejon, Philip, Mwacharo, Jedidah, Kai, Oscar, Mwangi, Tabitha, Milligan, Paul, Todryk, Stephen, Keating, Sheila, Lang, Trudie, Lowe, Brett, Gikonyo, Caroline, Molyneux, Catherine, Fegan, Greg, Gilbert, Sarah C, Peshu, Norbert, Marsh, Kevin, Hill, Adrian V. S
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617125/
https://www.ncbi.nlm.nih.gov/pubmed/17053830
http://dx.doi.org/10.1371/journal.pctr.0010029
_version_ 1782130509983252480
author Bejon, Philip
Mwacharo, Jedidah
Kai, Oscar
Mwangi, Tabitha
Milligan, Paul
Todryk, Stephen
Keating, Sheila
Lang, Trudie
Lowe, Brett
Gikonyo, Caroline
Molyneux, Catherine
Fegan, Greg
Gilbert, Sarah C
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S
author_facet Bejon, Philip
Mwacharo, Jedidah
Kai, Oscar
Mwangi, Tabitha
Milligan, Paul
Todryk, Stephen
Keating, Sheila
Lang, Trudie
Lowe, Brett
Gikonyo, Caroline
Molyneux, Catherine
Fegan, Greg
Gilbert, Sarah C
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S
author_sort Bejon, Philip
collection PubMed
description OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope–thrombospondin-related adhesion protein (ME-TRAP). DESIGN: The trial was randomised and double-blinded. SETTING: The setting was a rural, malaria-endemic area of coastal Kenya. PARTICIPANTS: We vaccinated 405 healthy 1- to 6-year-old children. INTERVENTIONS: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine). OUTCOME MEASURES: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/μl. RESULTS: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0–2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8–2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1–2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9–2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence. CONCLUSIONS: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas.
format Text
id pubmed-1617125
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-16171252007-04-12 A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya Bejon, Philip Mwacharo, Jedidah Kai, Oscar Mwangi, Tabitha Milligan, Paul Todryk, Stephen Keating, Sheila Lang, Trudie Lowe, Brett Gikonyo, Caroline Molyneux, Catherine Fegan, Greg Gilbert, Sarah C Peshu, Norbert Marsh, Kevin Hill, Adrian V. S PLoS Clin Trials Research Article OBJECTIVE: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope–thrombospondin-related adhesion protein (ME-TRAP). DESIGN: The trial was randomised and double-blinded. SETTING: The setting was a rural, malaria-endemic area of coastal Kenya. PARTICIPANTS: We vaccinated 405 healthy 1- to 6-year-old children. INTERVENTIONS: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine). OUTCOME MEASURES: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/μl. RESULTS: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0–2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8–2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1–2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9–2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence. CONCLUSIONS: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas. Public Library of Science 2006-10-20 /pmc/articles/PMC1617125/ /pubmed/17053830 http://dx.doi.org/10.1371/journal.pctr.0010029 Text en © 2006 Bejon et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bejon, Philip
Mwacharo, Jedidah
Kai, Oscar
Mwangi, Tabitha
Milligan, Paul
Todryk, Stephen
Keating, Sheila
Lang, Trudie
Lowe, Brett
Gikonyo, Caroline
Molyneux, Catherine
Fegan, Greg
Gilbert, Sarah C
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S
A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title_full A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title_fullStr A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title_full_unstemmed A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title_short A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
title_sort phase 2b randomised trial of the candidate malaria vaccines fp9 me-trap and mva me-trap among children in kenya
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617125/
https://www.ncbi.nlm.nih.gov/pubmed/17053830
http://dx.doi.org/10.1371/journal.pctr.0010029
work_keys_str_mv AT bejonphilip aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT mwacharojedidah aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT kaioscar aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT mwangitabitha aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT milliganpaul aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT todrykstephen aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT keatingsheila aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT langtrudie aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT lowebrett aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT gikonyocaroline aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT molyneuxcatherine aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT fegangreg aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT gilbertsarahc aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT peshunorbert aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT marshkevin aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT hilladrianvs aphase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT bejonphilip phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT mwacharojedidah phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT kaioscar phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT mwangitabitha phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT milliganpaul phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT todrykstephen phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT keatingsheila phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT langtrudie phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT lowebrett phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT gikonyocaroline phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT molyneuxcatherine phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT fegangreg phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT gilbertsarahc phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT peshunorbert phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT marshkevin phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya
AT hilladrianvs phase2brandomisedtrialofthecandidatemalariavaccinesfp9metrapandmvametrapamongchildreninkenya